Tempus AI to acquire Personalis for $1.5B, expanding MRD/oncology data
Tempus AI agreed on 2026-07-21 to acquire cancer-monitoring/MRD platform Personalis (NASDAQ: PSNL) in a $1.5B cash-and-stock merger, expanding Tempus's genomics/data-licensing lines. Confirmed via Yahoo Finance, builtinchicago.org, and Personalis's own Q2 2026 earnings coverage (merger announced alongside results). Tempus has no public self-serve price sheet (genomics is payer-reimbursed, data/apps are quoted) so this is not expected to move a listed price, but it materially expands the scope of Tempus's data-licensing business line.
Tempus AI announced on 2026-07-21 an agreement to acquire Personalis, a cancer-monitoring and minimal-residual-disease (MRD) detection platform, in a cash-and-stock merger valued at approximately $1.5B. The deal was confirmed consistently across Yahoo Finance, builtinchicago.org, DOTmed, and Personalis’s own Q2 2026 earnings coverage (Stock Titan, TradingView), which reported the merger alongside PSNL’s quarterly results (revenue up 30% YoY, widened net loss).
Because Tempus’s pricing is not public self-serve (genomics is payer/Medicare-reimbursed per-test; data licensing and AI apps are custom-quoted), this acquisition is unlikely to surface as a listed price change — but it materially expands Tempus’s precision-oncology data-licensing scope (adding Personalis’s MRD capability) and is worth noting on the page as an inorganic growth event.
Detection note: caught via Layer-0 Google-News corporate-event scanning — no pricing page carries public rate-card detail for either party, so Layer-1 diffing could not have surfaced this regardless. This entry closes the review loop.
Tempus agreed to acquire molecular-residual-disease (MRD) testing company Personalis for roughly $1.5B, folding MRD more tightly into its precision-oncology platform. As with Ambry and Paige, it is an M&A-as-moat move — deepening the licensable multimodal dataset and MRD menu (alongside Tempus's own xM) rather than changing a posted price; diagnostics pricing stays reimbursement-driven, so no immediate change to commercial terms was announced.